"The upside does not look like $20 to me, there is just too much else that has to be covered.  I'd say $5-7 US if all goes well, and ZERO if not."

Outstanding shares are ~111 million right now (~133 million including options/warrants/RSUs). $5-$7 CAD/share would give Resverlogix a market cap in the range of $555 million to $931 million CAD (depending upon whether you use the 111M or 133M number and where in the $5-$7 CAD range you lie). In my opinion, $5-$7 CAD is the short-term upside leading up to BETonMACE results in 2018. If BETonMACE results go as planned, the announcement of stellar topline results for BETonMACE will be much higher. Yes, there is financial baggage but the upside of a company with a drug that elicits cardioprotection the likes of the world has never seen (assuming it meets its Phase 3 endpoints), just has to be higher than a $1 billion market cap. My opinion is $1 billion market cap leading up to annoucement of results and $2-3 billion shortly after successful top-line results are announced. All in my opinion, do your own due diligience.

BearDownAZ